Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
J Pediatric Infect Dis Soc
; 13(2): 144-147, 2024 Feb 26.
Article
em En
| MEDLINE
| ID: mdl-38219024
ABSTRACT
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients. Clinical Trial Registration Clinicaltrials.gov, NCT03979313, https//clinicaltrials.gov/ct2/show/NCT03979313.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções Respiratórias
/
Vírus Sincicial Respiratório Humano
/
Infecções por Vírus Respiratório Sincicial
Tipo de estudo:
Clinical_trials
Limite:
Child
/
Humans
/
Infant
Idioma:
En
Revista:
J Pediatric Infect Dis Soc
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Israel